Phenotypes associated with this allele

• Allele Symbol: Pdpn^tm2.1Mlkn
• Allele Name: targeted mutation 2.1, Mark L Kahn
• Allele ID: MGI:5552845
• Summary: 4 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Pdpn^tm2.1Mlkn/Pdpn^tm2.1Mlkn Tg(CAG-cre/Esr1*)5Amc/0	involves: 129 * C57BL/6	MGI:5824831
cn2	Pdpn^tm2.1Mlkn/Pdpn^tm2.1Mlkn Rag1^tm1Mom/Rag1^tm1Mom Tg(Pdgfrb-cre)9Rha/0	involves: 129S7/SvEvBrd * C57BL/6	MGI:5552953
cn3	Pdpn^tm2.1Mlkn/Pdpn^tm2.1Mlkn Tg(Pdgfrb-cre)9Rha/0	involves: C57BL/6	MGI:5552952
cn4	Pdpn^tm2.1Mlkn/Pdpn^tm2.1Mlkn Tg(CAG-cre/Esr1*)5Amc/0	involves: C57BL/6 * CBA	MGI:5552951

Genotype
MGI:5824831

cn1

• Allelic Composition: Pdpn^tm2.1Mlkn/Pdpn^tm2.1Mlkn; Tg(CAG-cre/Esr1*)5Amc/0
• Genetic Background: involves: 129 * C57BL/6

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

VEGF-C-and galectin-8-induced lymphangiogenesis is diminished in Pdpn^tm2.1Mlkn/Pdpn^tm2.1Mlkn Tg(CAG-cre/Esr1*)5Amc/0 mice

immune system

abnormal lymphangiogenesis ( J:235778 )

• in corneal micropocket assays, corneas implanted with either VEGF-C or galectin-8 pellets in tamoxifen-treated mice exhibit significantly reduced lymphangiogenesis relative to similarly-implanted wild-type corneas, as quantified by the lymphatic vessel area on day 7 post-surgery

Genotype
MGI:5552953

cn2

• Allelic Composition: Pdpn^tm2.1Mlkn/Pdpn^tm2.1Mlkn; Rag1^tm1Mom/Rag1^tm1Mom; Tg(Pdgfrb-cre)9Rha/0
• Genetic Background: involves: 129S7/SvEvBrd * C57BL/6

immune system

absent lymphocyte ( J:205423 )

cardiovascular system

cardiovascular system phenotype ( J:205423 )

N • mice do not exhibit bleeding into mucosal lymph nodes unlike in Pdpn^tm2.1Mlkn/Pdpn^tm2.1Mlkn Tg(Pdgfrb-cre)9Rha mice

hematopoietic system

absent lymphocyte ( J:205423 )

Genotype
MGI:5552952

cn3

• Allelic Composition: Pdpn^tm2.1Mlkn/Pdpn^tm2.1Mlkn; Tg(Pdgfrb-cre)9Rha/0
• Genetic Background: involves: C57BL/6

cardiovascular system

lymph node hemorrhage ( J:205423 )

• bleeding in mucosal lymph nodes

immune system

lymph node hemorrhage ( J:205423 )

• bleeding in mucosal lymph nodes

Genotype
MGI:5552951

cn4

• Allelic Composition: Pdpn^tm2.1Mlkn/Pdpn^tm2.1Mlkn; Tg(CAG-cre/Esr1*)5Amc/0
• Genetic Background: involves: C57BL/6 * CBA

cardiovascular system

abnormal blood vessel morphology ( J:205423 )

• mucosal high endothelial venule (HEV) junctions in tamoxifen-treated mice resemble those of reactive peripheral HEVs

hemorrhage ( J:205423 )

• beginning at P15, tamoxifen-treated mice exhibit massive bleeding primarily in mucosal lymph nodes (mesenteric and cervical) but rarely in peripheral (inguinal and popliteal) lymph nodes with extravasation of red blood cells around high endothelial venules

• ovalbumin and CFA challenged tamoxifen-treated mice develop bleeding in draining peripheral lymph nodes of tamoxifen-treated mice

• treatment with Mel-14 reduces bleeding in draining peripheral lymph nodes of tamoxifen-treated mice

increased vascular permeability ( J:205423 )

• extravasation of red blood cells around high endothelial venules (HEVs) in lymph nodes from tamoxifen-treated mice

• FITC-dextran leaks from HEVs in tamoxifen-treated mice

• however, non-HEV blood vessels in lymph nodes and other organs do not leak FITC-dextran

immune system

abnormal lymph node morphology ( J:205423 )

• loss of mucosal and peripheral lymph nodes in tamoxifen-treated mice

absent peripheral lymph nodes ( J:205423 )

• loss of mucosal and peripheral lymph nodes in tamoxifen-treated mice